Rocatinlimab, administered subcutaneously, results in clinically meaningful improvements in patients with moderate-to-severe ...

If a current atopic dermatitis treatment isn’t working, it may be time for a change. Here’s how to confidently discuss new options for eczema with your healthcare team.

Enveda, a clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life's chemistry, today announced that it has initiated two ...

Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase ...

Rocatinlimab improved moderate to severe dermatitis in adults, establishing the OX40 receptor as a validated treatment target ...

Experts discuss the importance of balancing effective symptom control with quality of life in managing chronic pediatric atopic dermatitis, emphasizing personalized treatment plans that address both ...

Still itching after topical steroids? Here's why your atopic dermatitis symptoms may still be flaring and what you can do about it.

Up to 15 percent of children and five percent of adults are affected by the chronic inflammatory skin disease atopic dermatitis. Despite advanced therapy measures, the severe itching and eczema, ...

Early trial results show stapokibart improves paediatric atopic dermatitis with good tolerability. Find out more about its potential as a new treatment option.

Kymera Therapeutics has announced positive results from its trial of KT-621 to treat patients with moderate to severe atopic ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics (R) , today announced the close of its $25 million, twice-oversubscribed Series B ...